Dr. Eric Haura and Dr. Scott Antonia take us Behind The Science as they dive deep into the workings of the immune system and how it relates to cancer treatment and care.
Behind the Science -Episode 3 -Chapter 1 - The Immune System Introductions and how the immune system works.
"..or really the bigger problem is the cancer has developed ways to evade that immune system.."
Peregrine / CDMO KOL Scott Antonia co patent owner Dr James Mule which were both enticed to sell out their patent ....would this Dr James Mule have any business deals with current Avid Chairman Dr Joseph Carleone ?
Interesting how another PS Targeting KOL changed his mind about advancing PS Targeting ?? and those patents bought out are more interesting
KBI sold to TCR with the help of Joe McMahon and why have the current BODs remained silent ?
These guys have conflicts of interest it seems.....and will they follow fiduciary Duties at Peregrine, now Avid...CDMO?
CAR-TCR Summit Written by Admin | Sep 3, 2017 9:51:00 AM Sept 5-8, 2017 Boston, MA KBI Contact: David Monson
.....David Monson not responding back to requests about PS Targeting and CAR T adverse events/ TOXICITIES / and need for increased patient responders
________
.....funny how some investors for KBI buyout are not being disclosed
Name Joseph McMahon Title Chief Executive Officer Company Name KBI Biopharma Company Status Private & Independent Industry Biopharmaceutical Profile Profile Social Media Company News Facebook YouTube Funding History Company Transaction List
Mailing Address 1101 Hamlin Road Durham, NY 27704 USA Map Phone (919) 479-9898 Email Click for Free Trial Website www.kbibiopharma.com Company Description KBI Biopharma, founded in 1996, is a leading contract development organization for the biopharmaceutical industry. We accelerate and optimize drug development and manufacturing programs for our client partners, including global pharmaceutical and biotechnology companies and organizations in bio-defense.
Board Joe McMahon (Director) Joe is the President and CEO of Bioventure Partners, a growth advisory and investment firm, serving high-impact, technology driven organizations. Previously, Joe was with KBI Biopharma, a biopharmaceutical CDMO from 2002 until 2016, having served as its President and CEO. During this period, KBI grew from a startup to a 500+ person organization, serving over 300 biopharmaceutical companies globally. In 2015, Joe lead the sale of KBI Biopharma to JSR Corporation, a Tokyo-based multinational company. In 2016, Joe also lead the sale of kSep Systems (a KBI Biopharma cell therapy technology spinout), to Sartorius AG. Prior to KBI, Joe was a Vice President with Covance Biotechnology Services (a biopharmaceutical CDMO) from 1996 until 2002, including the sale of Covance Biotechnology Services to Akzo Nobel in 2001. Previously, Joe lead the engineering and technical services groups for a large medical device company.
Market Data 
Markets 
AI
